Aliases & Classifications for Somatization Disorder

MalaCards integrated aliases for Somatization Disorder:

Name: Somatization Disorder 12 74 15 71 32
Somatoform Disorders 43 32
Polysomatising Disorder 12
Somatisation Disorder 12
Somatoform Disorder 71
Briquet's Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13918
ICD9CM 34 300.81
MeSH 43 D013001
SNOMED-CT 67 397923000
ICD10 32 F45 F45.0
UMLS 71 C0037650 C0520482

Summaries for Somatization Disorder

Disease Ontology : 12 A somatoform disorder that involves persistently complaints of varied physical symptoms that have no identifiable physical origin.

MalaCards based summary : Somatization Disorder, also known as somatoform disorders, is related to somatoform disorder and social phobia, and has symptoms including multiple somatic complaints An important gene associated with Somatization Disorder is SOCS6 (Suppressor Of Cytokine Signaling 6), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics. The drugs Pregabalin and Histamine have been mentioned in the context of this disorder. Affiliated tissues include prostate, brain and testes.

Wikipedia : 74 Somatization disorder is a mental disorder characterized by recurring, multiple, and current, clinically... more...

Related Diseases for Somatization Disorder

Diseases related to Somatization Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 somatoform disorder 31.3 TAC1 SLC6A4 CRH
2 social phobia 31.1 SLC6A4 OXT MHRT
3 bruxism 30.5 TAC1 SLC6A4 HTR2A
4 obsessive-compulsive personality disorder 30.3 SLC6A4 HTR2A
5 depression 30.2 SLC6A4 HTR2A CRH
6 personality disorder 30.2 SLC6A4 HTR2A CRH
7 fibromyalgia 30.1 SLC6A4 HTR2A CRH
8 trigeminal neuralgia 30.1 TAC1 SLC6A4
9 chronic fatigue syndrome 30.0 SLC6A4 HTR2A CRH
10 dysthymic disorder 29.8 SLC6A4 SCLY HTR2A CRH
11 phobia, specific 29.8 SLC6A4 OXT MHRT CRH
12 hypochondriasis 29.7 SLC6A4 MHRT HTR2A
13 tobacco addiction 29.7 SLC6A4 HTR2A CRH
14 postpartum depression 29.7 SLC6A4 SCLY OXT CRH
15 irritable bowel syndrome 29.7 TAC1 SLC6A4 HTR2A CRH
16 post-traumatic stress disorder 29.6 SLC6A4 HTR2A CRH
17 substance abuse 29.6 SLC6A4 HTR2A CRH
18 borderline personality disorder 29.6 SLC6A4 HTR2A CRH
19 alcohol use disorder 29.5 SLC6A4 HTR2A CRH
20 mood disorder 29.5 SLC6A4 HTR2A CRH
21 neurotic disorder 29.4 SLC6A4 HTR2A FLNA
22 adjustment disorder 29.4 SLC6A4 SCLY HTR2A FLNA DCXR
23 panic disorder 29.4 TAC1 SLC6A4 HTR2A CRH
24 alexithymia 29.3 SLC6A4 OXT
25 eating disorder 29.3 SLC6A4 HTR2A CRH
26 mental depression 29.3 SLC6A4 SCLY OXT HTR2A CRH
27 constipation 29.3 TAC1 SLC6A4 HTR2A FLNA
28 anxiety 29.2 TAC1 SLC6A4 OXT HTR2A CRH
29 acute stress disorder 29.2 SLC6A4 OXT MHRT CRH
30 sexual disorder 29.2 SLC6A4 OXT HTR2A
31 body dysmorphic disorder 29.2 SLC6A4 OXT HTR2A
32 agoraphobia 29.1 SLC6A4 SCLY HTR2A CRH
33 alcohol dependence 29.1 SLC6A4 OXT HTR2A CRH
34 anorexia nervosa 29.1 SLC6A4 OXT HTR2A CRH
35 major depressive disorder 29.0 TAC1 SLC6A4 OXT HTR2A CRH
36 obsessive-compulsive disorder 28.8 SLC6A4 OXT HTR2A CRH
37 psychotic disorder 28.8 SLC6A4 OXT HTR2A
38 dissociative disorder 28.6 SLC6A4 SCLY OXT HTR2A DCXR
39 endogenous depression 28.6 SLC6A4 SCLY OXT HTR2A CRH
40 disease of mental health 28.4 TAC1 SLC6A4 OXT HTR2A CRH
41 migraine with or without aura 1 28.4 TAC1 SLC6A4 OXT HTR2A CRH
42 phobic disorder 28.0 SLC6A4 SCLY OXT MHRT HTR2A CRH
43 dissociative seizures 11.5
44 psychogenic movement 11.5
45 splenic flexure cancer 10.3 REG1A DCXR
46 chronic dacryocystitis 10.3 FLNA DCXR
47 dacryocystitis 10.3 FLNA DCXR
48 senile entropion 10.3 FLNA DCXR
49 acute inflammation of lacrimal passage 10.3 FLNA DCXR
50 senile ectropion 10.2 FLNA DCXR

Comorbidity relations with Somatization Disorder via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Anxiety
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Generalized Anxiety Disorder
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Irritable Bowel Syndrome Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Somatization Disorder:



Diseases related to Somatization Disorder

Symptoms & Phenotypes for Somatization Disorder

UMLS symptoms related to Somatization Disorder:


multiple somatic complaints

Drugs & Therapeutics for Somatization Disorder

Drugs for Somatization Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Flunarizine Approved Phase 4 52468-60-7 941361
4
Cycloserine Approved Phase 4 68-41-7 401 6234
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
7
Tibolone Approved, Investigational Phase 4 5630-53-5
8
Polyestradiol phosphate Approved Phase 4 28014-46-2
9
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
10
Citalopram Approved Phase 4 59729-33-8 2771
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
14
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
15 Anti-Anxiety Agents Phase 4
16 Calcium, Dietary Phase 4
17 calcium channel blockers Phase 4
18 Histamine Antagonists Phase 4
19
Histamine Phosphate Phase 4 51-74-1 65513
20 Vasodilator Agents Phase 4
21 Histamine H1 Antagonists Phase 4
22 Antitubercular Agents Phase 4
23 Antibiotics, Antitubercular Phase 4
24 Antimetabolites Phase 4
25 Estradiol 17 beta-cypionate Phase 4
26 Contraceptive Agents Phase 4
27 Antihypertensive Agents Phase 4
28 Contraceptive Agents, Male Phase 4
29 Contraceptives, Oral Phase 4
30 Androgen Antagonists Phase 4
31 Estradiol 3-benzoate Phase 4
32 Antineoplastic Agents, Hormonal Phase 4
33 Estrogen Receptor Modulators Phase 4
34 Anabolic Agents Phase 4
35 Androgens Phase 4
36 Estrogens Phase 4
37
Medroxyprogesterone Phase 4 520-85-4 10631
38 Antidepressive Agents Phase 4
39 Psychotropic Drugs Phase 4
40 Neurotransmitter Agents Phase 4
41 Serotonin Uptake Inhibitors Phase 4
42 abobotulinumtoxinA Phase 4
43 Cholinergic Agents Phase 4
44 Botulinum Toxins Phase 4
45 Botulinum Toxins, Type A Phase 4
46 Anesthetics Phase 4
47 Anesthetics, Local Phase 4
48 Immunologic Factors Phase 4
49 Hormones Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 243)
# Name Status NCT ID Phase Drugs
1 Neurologic Signatures of Chronic Pain Disorders Unknown status NCT02747940 Phase 4 flunarizine and/or pregabalin
2 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
3 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
4 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
5 The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder Recruiting NCT01822288 Phase 4 Tibolone;Estradiol & medroxyprogesterone acetate
6 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4 Normal Saline;Lidocaine Hydrochloride;Triamcinolone acetonide
7 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
8 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
9 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
10 A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment Withdrawn NCT00673972 Phase 4
11 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Unknown status NCT02390505 Phase 3 Vitamin C;Placebo
12 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
13 Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
14 Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck) Unknown status NCT00949065 Phase 3
15 The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period Unknown status NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
16 Treatment of Somatization in Primary Care Completed NCT00050583 Phase 3
17 Treatment of Patients With Chronic Functional Disorders. A Randomized Controlled Trial of Specialized Treatment Compared to Usual Care. Completed NCT00132197 Phase 2, Phase 3
18 Treating Refractory Symptoms in Primary Care (Hypochondriasis: Diagnosis, Description and Medical Care) Completed NCT00368212 Phase 3
19 A 16-week Prospective Randomised Double-blind Study on Facilitation of DYSPORT® Effect on Myofascial Pain Syndrome (MPS) by Electrical Stimulation. Completed NCT00246142 Phase 3
20 Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1 Completed NCT00166452 Phase 3 Lenalidamide
21 Efficacy of a Biopsychosocial Treatment for Somatizing Patients Carried Out by the General Practitioner Completed NCT00130988 Phase 3
22 Effectiveness of Diacutaneous Fibrolysis Technique on Pain, Range of Motion, Strength and Function in Patients With Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
23 Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome Completed NCT00919893 Phase 3 Cernilton;Placebo
24 Dysfunctional Illness-related Cognitions in Individuals With Hypochondriasis and Change Thereof Completed NCT01119469 Phase 3
25 Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder Completed NCT00149799 Phase 3 Escitalopram;Placebo
26 A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
27 Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I Completed NCT00817128 Phase 2, Phase 3
28 Great Trochanteric Pain Syndrome: Parallel Group, Blind Randomised Clinical Trial to Assess the Efficacy and Safety of PRP Injection Versus Needle Tenotomy With Lidocaine Recruiting NCT04231357 Phase 3 platelet rich plasma
29 A Prospective Randomized Study Comparing the Outcome of Electrical Stimulation of Vastus Medialis Obliquus Muscle and Physical Therapy vs Only Physical Therapy But no Electrical Stimulation in Patients With Patellofemoral Pain Syndrome Recruiting NCT03184545 Phase 3
30 Comparison of Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles in the Management of Myofascial Pain Disorder: A Randomized Clinical Trial Recruiting NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
31 A Prospective Randomized Controlled Pilot Study Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome Enrolling by invitation NCT03879538 Phase 3 Nitrous Oxide;Oxygen
32 Placebo-controlled Efficacy and Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS) Terminated NCT03560986 Phase 3 Neridronic acid;Placebo
33 Pharmacovigilance in Gerontopsychiatric Patients Terminated NCT02374567 Phase 3 Phenobarbital;Phenytoin;Carbamazepine;Oxcarbazepine;Valproic Acid;Lamotrigine;Topiramate;Gabapentin;Levetiracetam;Pregabalin;Lacosamide;Clonazepam;Biperiden;Levomepromazine;Fluphenazine;Perphenazine;Perazine;Thioridazine;Haloperidol;Melperone;Pipamperone;Bromperidol;Benperidol;Sertindole;Ziprasidone;Flupentixol;Chlorprothixene;Zuclopenthixol;Fluspirilene;Pimozide;Clozapine;Olanzapine;Quetiapine;Sulpiride;Tiapride;Amisulpride;Prothipendyl;Risperidone;Aripiprazole;Paliperidone;Diazepam;Oxazepam;Lorazepam;Bromazepam;Clobazam;Alprazolam;Hydroxyzine;Buspirone;Chloral Hydrate;Flurazepam;Nitrazepam;Triazolam;Lormetazepam;Temazepam;Midazolam;Brotizolam;Zopiclone;Zolpidem;Zaleplon;Melatonin;Clomethiazole;Diphenhydramine;Promethazine;Imipramine;Clomipramine;Opipramol;Trimipramine;Amitriptyline;Nortriptyline;Doxepin;Maprotiline;Amitriptyline oxide;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Escitalopram;Tranylcypromine;Moclobemide;Mianserin;Trazodone;Mirtazapine;Bupropion;Venlafaxine;Reboxetine;Duloxetine;Agomelatine;Pyritinol;Piracetam;Donepezil;Rivastigmine;Galantamine;Memantine;Nicergoline;Acamprosate;Lithium
34 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
35 Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient. Unknown status NCT01788176 Phase 2 Zoledronic acid;Placebo
36 Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome: an Open-label, Randomized, Delayed-start Clinical Trial Unknown status NCT02613247 Phase 2
37 Cognitive Affective Behavior Therapy for Somatization Completed NCT00149760 Phase 2
38 Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3) Completed NCT01518634 Phase 2 Imipramine treatment;Placebo
39 Cognitive Behavior Therapy for Somatization Disorder Completed NCT00276887 Phase 2
40 Evaluation of the Effects of a Body-centered Emotional Stimulation in Healthy Persons Completed NCT01187797 Phase 1, Phase 2
41 A Phase II Multicentre Multinational Prospective Randomised Double-blind Placebo-controlled Study Assessing the Efficacy and Safety of a Single Application of Three Doses of Dysport® in Patients With Upper Back Myofascial Pain Syndrome Completed NCT00134810 Phase 2
42 A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed NCT00067743 Phase 2 Lenalidomide
43 A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
44 Quadriceps Femoris Strengthening Versus Hamstring Stretching for Patellofemoral Pain Syndrome: A Randomized Clinical Trial. Completed NCT01691170 Phase 1, Phase 2
45 A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Completed NCT03282318 Phase 2 ASP6294;Placebo
46 Treatment for Patellofemoral Pain Syndrome Using Knee Abduction Moment-Reducing Footwear Completed NCT01332110 Phase 1, Phase 2
47 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
48 The Impact of Cardiac Rehabilitation on Angina Frequency, Psychological Morbidity and Quality of Life in Women With Syndrome X Completed NCT00123617 Phase 2
49 10% Sinecatechins Ointment, a Botanical Drug Derived From Green Tea, for the Treatment of Significant to Severe Secondary Provoked Vestibulodynia in Sexually Active, Post-Menopausal Women With Vulvovaginal Atrophy Recruiting NCT03682601 Phase 2 Sinecatechins Topical
50 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome Active, not recruiting NCT03990649 Phase 2 TAK-935;TAK-935 Placebo

Search NIH Clinical Center for Somatization Disorder

Cochrane evidence based reviews: somatoform disorders

Genetic Tests for Somatization Disorder

Anatomical Context for Somatization Disorder

MalaCards organs/tissues related to Somatization Disorder:

40
Prostate, Brain, Testes, Spinal Cord, Dorsal Root Ganglion, Eye, Liver

Publications for Somatization Disorder

Articles related to Somatization Disorder:

(show top 50) (show all 1955)
# Title Authors PMID Year
1
Prospective pilot study to identify psychological factors influencing peri-operative pain in total knee arthroplasty (TKA). 61
32266414 2020
2
Life satisfaction in persons with mental disorders. 61
32556822 2020
3
Comorbidities of Patients with Functional Somatic Syndromes Before, During and After First Diagnosis: A Population-based Study using Bavarian Routine Data. 61
32555301 2020
4
Treatment of somatic symptom disorder in childhood: evidence-based psychotherapy interventions 61
32516123 2020
5
Mental Disorders and Suicide Risk among Cancer Patients: A Nationwide Cohort Study. 61
32538322 2020
6
Determinants of Suicidality in the European General Population: A Systematic Review and Meta-Analysis. 61
32526975 2020
7
Psychiatric characteristics of older persons with medically unexplained symptoms: A comparison with older patients suffering from medically explained symptoms. 61
32431253 2020
8
A comparison of patients with somatic symptom disorder attending psychiatric services and those unwilling to attend psychiatric services. 61
32474346 2020
9
[The role of the general practitioner in management of psychiatric disorders]. 61
32475623 2020
10
Managing mental health on a prolonged deployment: UK military exercise SAIF SAREEA 3. 61
32474439 2020
11
Psychiatric Morbidities of Elderly Out-patients Attending Various Outreach Clinics in Gandaki Province of Nepal: A Descriptive Cross-sectional Study. 61
32538926 2020
12
Somatic Symptom Disorder, Medically Unexplained Symptoms, Somatoform Disorders, Functional Neurological Disorder: How DSM-5 Got It Wrong. 61
32191123 2020
13
Incidence of and factors associated with manic episodes and bipolar disorder in the decade following depression onset in Germany. 61
32056923 2020
14
Parent-youth conflict as a predictor of depression in adulthood: a 15-year follow-up of a community-based cohort. 61
31302772 2020
15
The Influence of Socio-Demographic Factors, Lifestyle and Psychiatric Indicators on Adherence to Treatment of Patients with Rheumatoid Arthritis: A Cross-Sectional Study. 61
32295226 2020
16
Quality of life, level of functioning, and its relationship with mental and physical disorders in the elderly: results from the MentDis_ICF65+ study. 61
32143635 2020
17
Shame, dissociative seizures and their correlation among traumatised female Yazidi with experience of sexual violence. 61
32345408 2020
18
[Temporal, socio-demographic and diagnostic profile of psychologically assisted cases at an Emergency Medical Service - Jujuy.] 61
32238255 2020
19
Psychological disturbances in patients with pigmentary disorders: a cross-sectional study. 61
31566833 2020
20
Psychosocial and Somatoform Disorders. 61
32181735 2020
21
Quantitative Sensory Testing in Patients with Multisomatoform Disorder with Chronic Pain as the Leading Bodily Symptom-a Matched Case-Control Study. 61
31578559 2020
22
Patients with chronic urticaria have a higher risk of psychiatric disorders: a population-based study. 61
31220338 2020
23
Clinical Practice Guideline: Psychotherapies for Somatoform Disorders. 61
32055068 2020
24
[Non specific complaints. Somatization disorder or somatic disease?] 61
31960307 2020
25
[Body Dysmorphic Disorder - Balance between Beauty Mania and Illness]. 61
32456576 2020
26
An empirically derived recommendation for the classification of body dysmorphic disorder: Findings from structural equation modeling. 61
32492037 2020
27
Detecting DSM-5 somatic symptom disorder: criterion validity of the Patient Health Questionnaire-15 (PHQ-15) and the Somatic Symptom Scale-8 (SSS-8) in combination with the Somatic Symptom Disorder - B Criteria Scale (SSD-12). 61
30729902 2020
28
[Internal medicine between soma and psyche : Functional bodily complaints and depressive disorders in outpatient care]. 61
31853579 2020
29
Factors influencing adherence to therapeutic recommendations made after diagnostic reassessment of medically unexplained symptoms in children and adolescents. 61
30818976 2020
30
Addressing Mental Health Concerns in Primary Care: Practices Among Medical Residents in a Rural Setting. 61
30758698 2019
31
Mental health conditions diagnosed before bilateral oophorectomy: a population-based case-control study. 61
31479036 2019
32
Emotion Regulation Strategies in Depression and Somatization Disorder. 61
30304997 2019
33
Assessing somatization in urologic chronic pelvic pain syndrome. 61
31823813 2019
34
Multisensory mechanisms of body perception in somatoform disorders. 61
31644956 2019
35
Orthorexic eating behavior in patients with somatoform disorders. 61
31833044 2019
36
The relationship between somatic sense perception levels and comorbid psychiatric diseases in chronic pain patients. 61
31741346 2019
37
The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS). 61
31248601 2019
38
Anxiety is the cause of the worse outcomes of allergic patients after total knee arthroplasty. 61
31722034 2019
39
Changes in brain glucose metabolism and connectivity in somatoform disorders: an 18F-FDG PET study. 61
31720787 2019
40
Mindfulness and Acceptance-Based Group Therapy: An Uncontrolled Pragmatic Pre-Post Pilot Study in a Heterogeneous Population of Female Prisoners. 61
31238758 2019
41
Implementation of outcome measurement (HoNOS) in an outpatient psychiatric clinic in Sligo/Leitrim mental health service. 61
30980222 2019
42
Hospital length of stay among older people treated with flexible and integrative psychiatric service models in Germany. 61
31276239 2019
43
Associations of psychosis-risk symptoms with quality of life and self-rated health in the Community. 61
31586798 2019
44
Posttraumatic stress reactions of underground drivers after suicides by jumping to arriving trains; feasibility of an early stepped care outpatient intervention. 61
30963791 2019
45
[Gastrointestinal somatoform disorders]. 61
31519027 2019
46
Small atrial septal defects are associated with psychiatric diagnoses, emotional distress, and lower educational levels. 61
31136098 2019
47
Association between ambient PM2.5 and emergency department visits for psychiatric emergency diseases. 61
30522934 2019
48
[Sinus Tachycardia in the Adolescent: The Importance of Differential Diagnosis]. 61
31445536 2019
49
Re: Jing et al., the efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: A meta-analysis of randomized controlled trials. 61
30819582 2019
50
Individuals with currently untreated mental illness: causal beliefs and readiness to seek help. 61
29335036 2019

Variations for Somatization Disorder

Expression for Somatization Disorder

Search GEO for disease gene expression data for Somatization Disorder.

Pathways for Somatization Disorder

Pathways related to Somatization Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.01 TAC1 SLC6A4 HTR2A
2 10.4 SLC6A4 HTR2A

GO Terms for Somatization Disorder

Cellular components related to Somatization Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 8.92 TAC1 HTR2A FLNA CRH

Biological processes related to Somatization Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 9.63 TAC1 OXT HTR2A
2 associative learning GO:0008306 9.48 TAC1 CRH
3 response to pain GO:0048265 9.43 TAC1 CRH
4 memory GO:0007613 9.43 SLC6A4 OXT HTR2A
5 positive regulation of ossification GO:0045778 9.4 TAC1 OXT
6 positive regulation of renal sodium excretion GO:0035815 9.37 TAC1 OXT
7 sleep GO:0030431 9.32 OXT HTR2A
8 sperm ejaculation GO:0042713 9.16 SLC6A4 OXT
9 response to ether GO:0045472 8.96 OXT CRH
10 positive regulation of corticosterone secretion GO:2000854 8.62 TAC1 CRH

Molecular functions related to Somatization Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 OXT CRH
2 serotonin binding GO:0051378 8.62 SLC6A4 HTR2A

Sources for Somatization Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....